Wellstar to partner with U.S. government for COVID therapy

Submitted information:

Wellstar Health System, one of the largest and most integrated health systems in Georgia, in partnership with the U.S. Department of Health and Human Services (HHS), announced that it is expanding access to COVID-19 monoclonal antibody (mAb) therapies at several of its eleven existing infusion locations, with Wellstar Cherokee Health Park being the first Wellstar facility to launch this program. Wellstar is the first healthcare provider in Georgia to join the mAb Health Equity Initiative.
Wellstar Health System is first expanding access to the mAb infusion treatment for eligible patients at Wellstar Cherokee Health Park, effective October 29, with additional locations rolling out in the coming weeks. With the expansion, Wellstar will be able to substantially increase the total number of patients receiving the therapy. Patients can receive the mAb treatment at Wellstar Cherokee Health Park location seven days a week from 8:00 a.m. to 7:30 p.m. To confirm eligibility for the treatment and book an appointment, patients should contact 770-956-STAR (770-956-7827).
If administered within 10 days of the onset of COVID-19 symptoms, the one-time therapy – administered through infusion – has been shown to be highly effective in neutralizing the virus and preventing symptoms from worsening. MAb treatment is used to help prevent the progression of the disease that might otherwise require hospitalization for people who are at high risk for developing severe COVID-19 illness and have tested positive for the COVID-19 virus or are unvaccinated and have been exposed to someone who has tested positive.

On March 17, 2021, HHS announced it was investing $150 million to increase access to mAb therapy for high-risk patients in underserved and disadvantaged communities across the country. With support from KPMG LLP, HHS is developing new prototype models for expanding access to mAb treatment, leveraging an existing network of healthcare partners, including Wellstar.
The therapy is the first COVID-19 treatment granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for outpatient use. A Phase 3 clinical trial showed that the antibody therapy reduced the risk of hospitalization or death by up to 70% in patients who received the drug intravenously compared to those who received a placebo.
To be eligible for mAb treatment, patients must meet the EUA definition of “high risk.” The FDA Emergency Use Authorization provides additional information on eligibility for mAb treatment. Treatment is offered regardless of immigration status, health insurance coverage, or ability to pay.
ABOUT CRUSH COVID
A treatment for COVID-19 is here and is available in every state at hundreds of locations across the country. With the help of KPMG, the U.S. Department of Health and Human Services (HHS), state and local health departments, and local hospitals and health clinics, eligible patients will have increased access to mAb treatment in a growing number of underserved and disadvantaged communities through this initiative. Authorized by the FDA, monoclonal antibody therapy (mAb) is available to patients who have tested positive for COVID-19 and are considered at high risk for progressing to severe COVID-19 and/or hospitalization.
To learn more about eligibility and find a treatment location near you, visit https://crushcovid.com.
Related stories

Every Sunday we round up the week’s top headlines and preview the upcoming week in the East Cobb News Digest. Click here to sign up, and you’re good to go!